Search Results

You are looking at 111 - 120 of 480 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

CLO23-062: Pediatric Metastatic Pulmonary Adenocarcinoma

Luke Proctor, Arjith Rathakrishnan, Claudia Zapata, and KanwarAnoop Kainaur

chemotherapy as per Keynote-407 (pembrolizumab, carboplatin and paclitaxel) due to continuous effusions, followed by protocol Keynote-189 (pembrolizumab, cisplatin, pemetrexed). Once his molecular testing revealed an EML4-ALK fusion, he was switched to oral

Full access

HSR21-055: Treatment Patterns and Healthcare Resource Utilization in First-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma in Asian and Western Countries

Dena Jaffe, Marc DeCongelio, and Joseph Gricar

(Asia=71.1%; West=89.0%). The five most common 1L treatment regimens were cisplatin + 5-FU (27.4%), carboplatin + paclitaxel (8.4%), FOLFOX (8.0%), 5-FU (+leucovorin) (6.6%), and carboplatin + 5-FU (5.9%), although differences were observed by geography

Full access

BIO20-027: Comparison of Treatment Plans Feasible Through AI Enabled Multidisciplinary Online Tumor Board Solution vs. NCCN Based Clinical Decision Support System (CDSS)

Naresh Ramarajan, CS Pramesh, Gitika Srivastava, Vikas Ostwal, Anant Ramaswamy, Aju Mathew, Mahesh Goel, Supriya Chopra, BJ Sunil, Durgatosh Pandey, Rajendra A. Badwe, and Bhawna Sirohi

recommended a patient-specific treatment plan that was not part of NCCN. Specific substitutions such as Capecitabine for 5-FU, Carboplatin for Cisplatin, and Paclitaxel for Docetaxel that were not part of NCCN were made to for patient tolerance of therapy

Full access

Cervical Cancer

Benjamin E. Greer, Wui-Jin Koh, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Warner K. Huh, Daniel S. Kapp, John R. Lurain III, Lainie Martin, Mark A. Morgan, Robert J. Morgan Jr., David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr., Nelson Teng, and Fidel A. Valea

to single-agent platinum therapy. 111 , 112 Cisplatin-based combination chemotherapy regimens, such as cisplatin/paclitaxel and cisplatin/topotecan, have been extensively investigated in clinical studies. 111 , 112 , 114 – 116 A randomized phase

Full access

Management of Patients With Lung Cancer and Poor Performance Status

Ajeet Gajra, Alissa S. Marr, and Apar Kishor Ganti

study evaluating carboplatin and 1 of 2 paclitaxel formulations in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) and a marginal PS found a significant difference in OS based on the geographic location of the patients. 8

Full access

Surviving the Perfect Storm: An RVU-Based Model to Evaluate the Continuing Impact of MMA on the Practice of Oncology

David M. Dunning and Thomas A. Paivanas

://www.ama-assn.org/ama/pub/category/3113.html . Accessed November 2005 . 10. Langer CJ Leighton JC Comis RL . Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis . J Clin

Full access

Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

Rosalyn A. Juergens and Julie R. Brahmer

CP . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N Engl J Med 2002 ; 346 : 92 – 98 . 4. Sandler AB Gray R Brahmer J . Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or

Full access

Ten Years of Progress Against Breast Cancer: A Partnership of Basic and Clinical/Translational Science

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

cancer. These include nab -paclitaxel, eribulin, and ixabepilone. Evolution of HER2-Targeted Therapy The use of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2, in combination with chemotherapy in the

Full access

Oncology Research Program

pharmacokinetics of carboplatin and pralatrexate used in combination Contact: Marcela G. del Carmen, MD, MPH • 617-724-4800 • mdelcarmen@partners.org ClinicalTrials.gov Identifier: NCT01188876 Neoadjuvant Weekly nab-Paclitaxel (Abraxane) Plus

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Neoadjuvant Weekly nab-Paclitaxel (Abraxane) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide With